Medtech Pharma (India) Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 26 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.55 Cr
- Revenue Growth 0.19%
- Profit Growth 8.06%
- Ebitda 46.65%
- Net Worth 7.87%
- Total Assets 18.51%
About Medtech Pharma (India)
Medtech Pharma (India) Private Limited (MPIPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 17 March 1998 and has a history of 26 years and ten months. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹4.55 Cr.
Utpla and Lokesh Mehta serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U74900DL1998PTC092763
- Company No.
092763
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Mar 1998
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Medtech Pharma (India)?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Lokesh Mehta  | Director | 01-Nov-2011 | Current |
| Utpla | Director | 01-Jun-2003 | Current |
Financial Performance of Medtech Pharma (India).
Medtech Pharma (India) Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 0.19% increase. The company also saw a slight improvement in profitability, with a 8.06% increase in profit. The company's net worth moved up by a moderate rise of 7.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medtech Pharma (India)?
In 2023, Medtech Pharma (India) had a promoter holding of 98.00% and a public holding of 2.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹45.50 M
₹0
Charges Breakdown by Lending Institutions
- Others : 4.55 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 23 Sep 2020 | Others | ₹3.50 M | Open |
| 18 Jan 2019 | Others | ₹4.20 Cr | Open |
How Many Employees Work at Medtech Pharma (India)?
Unlock and access historical data on people associated with Medtech Pharma (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medtech Pharma (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medtech Pharma (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
